Novartis: Sandoz to market multiple sclerosis drug
(CercleFinance.com) - Sandoz has entered an agreement with Polpharma giving the Novartis generics unit commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis.
Under the agreement, the Polish drugmaker will maintain responsibilities for development and manufacturing, while Sandoz will commercialize and distribute the product in all markets upon its approval.
The multiple sclerosis drug is currently in Phase III clinical development.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Under the agreement, the Polish drugmaker will maintain responsibilities for development and manufacturing, while Sandoz will commercialize and distribute the product in all markets upon its approval.
The multiple sclerosis drug is currently in Phase III clinical development.
Copyright (c) 2019 CercleFinance.com. All rights reserved.